Immunotech Biopharm Ltd (HKG:6978)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.590
+0.020 (0.78%)
Feb 13, 2026, 11:53 AM HKT
Market Cap1.60B +29.0%
Revenue (ttm)n/a
Net Income-244.91M
EPS-0.48
Shares Out617.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume40,000
Average Volume306,812
Open2.440
Previous Close2.570
Day's Range2.440 - 2.590
52-Week Range2.380 - 6.150
Beta0.56
RSI46.86
Earnings DateMar 27, 2026

About Immunotech Biopharm

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. The company’s core product is EAL, a multi-target cellular immunotherapy product that is in Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer. It also develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 173
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6978
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements